美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Voxelotor	Tablet	II (Paddle)	75	50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS)	900	5, 10, 20, 30 and 45	2022/07/28
Voxelotor	Tablet, for Suspension	II (Paddle)	75	50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS)	900	5, 10, 15, 20 and 30	2022/07/28
Warfarin Sodium	Tablet			Develop a dissolution method			2024/01/03
Zafirlukast	Tablet	II (Paddle)	50	1% w/v Aqueous Sodium Dodecyl Sulfate	1000	10. 30, 30 and 45	2007/10/09
Zalcitabine	Tablet			Develop a dissolution method			2024/01/03
Zaleplon	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Zidovudine	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Zileuton	Tablet			Develop a dissolution method			2023/09/15
Zileuton	Tablet (Extended Release)			Develop a dissolution method			2023/09/15
Zinc Acetate	Capsule	II (Paddle)	50	0.1 N HCl	900	10, 20, 30 and 45	2004/02/19
Ziprasidone HCl	Capsule	II (Paddle)	75	Tier I: 0.05 M Na phosphate buffer, pH 7.5 + 2% SDS (w/w) Tier II: 0.05 M Na phosphate buffer, pH 7.5 (700ml) + 1% pancreatin. After 15 min. incubation, add 200 mL of phosphate buffer containg 9% SDS	900	10, 20, 30, 45 and 60	2006/03/04
Zolmitriptan	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Zolmitriptan	Tablet (Orally Disintegrating)	II (Paddle)	50	0.1 N HCl	500	5, 10, 15, 20 and 30	2007/06/18
Zolpidem Tartrate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Zolpidem Tartrate	Tablet (Extended Release)			Refer to USP			2012/01/05
Zolpidem Tartrate (1.75 and 3.5 mg)	Tablet (Sublingual)	II (Paddle)	50	Simulated intestinal fluid (without enzyme), pH 6.8, (deaerated)	500	1, 3, 5, 7, 10 and 15	2014/08/14
Zolpidem Tartrate (5 and 10 mg)	Tablet (Sublingual)	II (Paddle)	75	Phosphate Buffer, pH 6.8	900	1, 3, 5, 7, 10 and 15	2014/08/14
Zonisamide	Capsule			Develop a dissolution method			2023/09/15